Experimental injection for hard-to-treat autoimmune diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You need a diagnosis of one of these autoimmune diseases: lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA-associated vasculitis.
- Your usual treatments must not be working well, or you need to take high-dose steroids to control your condition.
- Your heart, lungs, kidneys, and liver must be functioning within acceptable limits for this study.
- You must be willing to use effective birth control during the study and for one year after the infusion.
- You must not have had CAR-T cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called JY231 for people with certain autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, dermatomyositis, or vasculitis that haven't improved with standard treatments. The goal is to see if JY231 can help control the disease when other options haven't worked.
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
This trial tests an experimental injection (called WGb-0301) to see if it can help people with autoimmune diseases like lupus or scleroderma that have not improved with usual treatments. The goal is to find a new option for those who have run out of standard therapies.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.